Accessibility Menu
Passage Bio logo

Passage Bio(NASDAQ) PASG

Current Price$4.92
Market Cap$15.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year-13%
1 Month-14%
Passage Bio last closing stock price
MetricPriceDate
Last closeUSD 4.922026-07-22
Passage Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.2%USD 4.912026-07-15
1 month-13.99%USD 5.722026-06-22
3 month-16.61%USD 5.902026-04-23
Year to date-58.31%USD 11.802025-12-31
1 year-13.23%USD 5.672025-07-22
3 year-75.23%USD 19.862023-07-21
5 year-98.07%USD 254.602021-07-23
Since inception-98.89%USD 444.002020-02-28

Passage Bio Financials at a Glance

Market Cap

$15.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$37.68M

EPS (TTM)

-$11.84

P/E Ratio

-0.42

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$4.92

Volume

1

Open

$4.92

Previous Close

$4.92

Daily Range

$4.92 - $4.92

52-Week Range

$3.29 - $20.00

Estimated Earnings Date

Aug 11, 2026

PASG News

Balance Sheet 2

Here's Why Shares of Passage Bio Dropped Today

Brian Orelli, PhDJan 22, 2021
IPO - GettyImages-1065255374

The Coronavirus Pandemic Will Delay 2020 IPOs

Joe TenebrusoMar 15, 2020
HighlyDetailedDNA

Gene Therapy Biotech Passage Bio IPOs

Brian Orelli, PhDFeb 28, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Passage Bio

Passage Bio, Inc. is a biotechnology company focused on developing genetic medicines for neurodegenerative diseases. Their mission is to advance gene therapies targeting the root causes of these conditions, with their leading candidate, PBFT02, aimed at treating frontotemporal dementia and potentially other neurodegenerative disorders.

Products and Services

PBFT02: A gene therapy for frontotemporal dementia targeting progranulin deficiency.

Future indications: Potential expansion of PBFT02 for ALS, Alzheimer’s, and other neurodegenerative diseases.

Current manufacturing collaboration: Use of Catalent’s facilities for gene therapy production.

What Makes Passage Bio, Inc. Special

Passage Bio's key differentiator lies in its partnership with the University of Pennsylvania and genetic medicine expert Dr. James Wilson, providing access to cutting-edge gene therapy research and development capabilities. This collaboration underpins their innovative approach to targeting central nervous system disorders using advanced gene therapy techniques.

Five Things You Need to Know

The company's lead product, PBFT02, is in clinical trials for frontotemporal dementia.

Passage Bio has exclusive rights to certain programs developed with the University of Pennsylvania.

Their research strategy focuses on using adeno-associated virus vectors for gene delivery.

PBFT02 has received Orphan Drug and Fast Track Designations for FTD from the FDA.

They have paused clinical development of PBGM01, PBKR03, and PBML04 to focus resources.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

William Chou, MD, MBA

Website

www.passagebio.com

Headquarters

Philadelphia, PA 19103, US

PASG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-150.88%

Return on Capital

-100.90%

Return on Assets

-103.33%

Earnings Yield

-2.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.21M

Volume

1

Avg. Volume

88.78K

Financials (TTM)

Gross Profit

-$329.00K

Operating Income

-$41.72M

EBITDA

-$34.22M

Operating Cash Flow

-$30.65M

Capital Expenditure

$0.00

Free Cash Flow

-$30.65M

Cash & ST Invst.

$33.34M

Total Debt

$5.76M

Passage Bio Performance Analysis

Passage Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Passage Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Passage Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -50.02-28.0%
20232023-12-31USD -37.29-25.5%
20242024-12-31USD -21.44-42.5%
20252025-12-31USD -14.35-33.1%
Passage Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.3%
Q32025-09-3017.2%
Q42025-12-31-66.5%
Q12026-03-3142.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$129.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$658.63K

N/A

Employees

24

N/A

Net Income

-$7.56M

+50.9%

EBITDA

-$7.43M

+45.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$33.34M

-47.4%

Total Debt

$5.76M

-77.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.61M

-78.6%

Short Term Debt

$1.15M

-68.4%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-2.55%

N/A

Free Cash Flow

-$12.99M

+6.2%

Operating Cash Flow

-$12.99M

+6.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LSTALisata Therapeutics, Inc.
$2.09-5.00%
ALLRAllarity Therapeutics, Inc.
$1.24-3.13%
XCURExicure, Inc.
$1.70-3.40%
GDTCCytoMed Therapeutics Limited
$0.90-6.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.87-0.28%
NOKNokia
$9.84-0.04%
TAT&T
$22.93-0.00%
ONDSOndas
$7.82-0.02%

Questions About PASG

What is the current price of Passage Bio?

Passage Bio is trading at $4.92 per share.

What is the 52-week range for Passage Bio?

Over the past 52 weeks, Passage Bio has traded between $3.29 and $20.00.

How much debt does Passage Bio have?

As of the most recent reporting period, Passage Bio reported total debt of $5.76M.

How much cash does Passage Bio have on hand?

Passage Bio reported $33.34M in cash and cash equivalents in its most recent financial results.

What is Passage Bio’s dividend yield?

Passage Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services